Evidence map›Paper›PMID 39901306›Full record

ReviewStem cell research & therapy2025

Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights.

Akram Hoseinzadeh, Seyed-Alireza Esmaeili, Reza Sahebi, Anahita Madani Melak, Mahmoud Mahmoudi, Maliheh Hasannia, Rasoul Baharlou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. The double-positive cells in the tumor microenvironment.Journal of translational internal medicine · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Akram HoseinzadehDepartment of Immunology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Seyed-Alireza EsmaeiliDepartment of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Reza SahebiDepartment of Modern Sciences and Technologies, Mashhad University of Medical Sciences, Mashhad, Iran.
Anahita Madani MelakDepartment of Biology, Kavian Institute of Higher education, Mashhad, Iran.
Mahmoud MahmoudiDepartment of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Maliheh HasanniaCancer Research Center, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Rasoul BaharlouDepartment of Immunology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran. Rasoulbaharlou195@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A large body of evidence suggests that mesenchymal stromal cells (MSCs) are able to respond rapidly to the cytokine milieu following systemic infusion. This encounter has the potential to dictate their therapeutic efficacy (also referred to as licensing). MSCs are able to rapidly react to cellular damage by migrating to the inflamed tissue and ultimately modifying the inflammatory microenvironment. However, the limited use of MSCs in clinical practice can be attributed to a lack of understanding of the fate of MSCs in patients after administration and long term MSC-derived therapeutic activity. While the known physiological effectors of viable MSCs make a relative contribution, an innate property of MSCs as a therapeutic agent is their caspase-dependent cell death. These mechanisms may be involving the functional reprogramming of myeloid phagocytes via efferocytosis, the process by which apoptotic bodies (ABs) are identified for engulfment by both specialized and non-specialized phagocytic cells. Recent studies have provided evidence that the uptake of ABs with a distinct genetic component can induce changes in gene expression through the process of epigenetic remodeling. This phenomenon, known as 'trained immunity', has a significant impact on immunometabolism processes. It is hypothesized that the diversity of recipient cells within the inflammatory stroma adjacent to MSCs may potentially serve as a biomarker for predicting the clinical outcome of MSC treatment, while also contributing to the variable outcomes observed with MSC-based therapies. Therefore, the long-term reconstructive process of MSCs may potentially be mediated by MSC apoptosis and subsequent phagocyte-mediated efferocytosis.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsApoptosisHumansPhagocytosisAntimicrobial peptideApoptosisApoptotic bodiesAutophagyEfferocytosisImmunoregulationLong-term effectivenessMesenchymal stem cells

Identifiers

PMID39901306
PMCPMC11792531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.